This study identifies the compound napabucasin as a promising candidate against refractory Helicobacter pylori infections, demonstrating efficacy compared to standard triple therapy in murine infection models, and probing the mechanism of action.
- Xudong Hang
- Weiqi Lan
- Hongkai Bi